ABINGEM-1gm (Gemcitabine Powder for Solution for Infusion 1g)

Manufacturer
Naprod Life Sciences Private Limited(INDIA)

Registraction Number
MAL24116014AZ

Content:
ABINGEM-1gm (Gemcitabine Powder for Solution for Infusion 1g) contains gemcitabine hydrochloride, equivalent to 1 g gemcitabine.
Inactive Ingredients: May include excipients like sodium chloride for reconstitution (specifics depend on the manufacturer).

Indications:

• Bladder Cancer: Treatment of locally advanced or metastatic bladder cancer in combination with cisplatin.
• Pancreatic Cancer: Treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
• Non-Small Cell Lung Cancer (NSCLC): First-line treatment of patients with locally advanced or metastatic NSCLC in combination with cisplatin.
• Ovarian Cancer: Treatment of locally advanced or metastatic epithelial ovarian carcinoma in combination with carboplatin in patients with relapsed disease.
• Breast Cancer: Treatment of unresectable, locally recurrent, or metastatic breast cancer in combination with paclitaxel in patients experiencing a relapse after adjuvant/neoadjuvant chemotherapy.

1. Dosage: The recommended dose for gemcitabine is 1000 mg/m², given as a 30-minute infusion. The dose should be given on days 1, 8, and 15 of each 28-day cycle in combination with cisplatin.
2. Administration: Administer by intravenous infusion following reconstitution. Only healthcare professionals with appropriate training should administer this medication.
3. Consistency: Follow the prescribed regimen closely.
4. Monitoring: Regular monitoring for side effects and effectiveness is essential.